ALID (Allied) EBITDA Margin %: -1,889.29% (As of Nov. 2024)

What is Allied EBITDA Margin %?

Allied ALID -99.80% EBITDA Margin % is -1,889.29% as of Nov. 2024.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Allied's EBITDA for the three months ended in Nov. 2024 was $-0.53 Mil. Allied's Revenue for the three months ended in Nov. 2024 was $0.03 Mil. Therefore, Allied's EBITDA margin for the quarter that ended in Nov. 2024 was -1,889.29%.

Allied (OTCPK:ALID) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Allied EBITDA Margin % Related Terms

Allied EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Allied's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allied EBITDA Margin % Chart

Allied Annual Data

Trend

Mar18

Mar19

Aug20

Aug21

Aug22

Aug23

Aug24

EBITDA Margin %

Get a 7-Day Free Trial

0.00

-60,362.50

-8,567.47

-13,437.50

-3,112.50

Allied Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
EBITDA Margin %	Get a 7-Day Free Trial															-3,105.26	0.00	-762.34	0.00	-1,889.29

ALID vs CBDY, PLSH, STEK: EBITDA Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allied's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allied EBITDA Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Allied's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Allied's EBITDA Margin % falls into.

Save Embed

Allied EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Allied's EBITDA Margin % for the fiscal year that ended in Aug. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Aug. 2024 )	/	Revenue (A: Aug. 2024 )
	=	-2.988	/	0.096
	=	-3,112.50 %

Allied's EBITDA Margin % for the quarter that ended in Nov. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Nov. 2024 )	/	Revenue (Q: Nov. 2024 )
	=	-0.529	/	0.028
	=	-1,889.29 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -1,889.29% mean?

Allied (ALID) has a EBITDA Margin % of -1,889.29% as of Nov. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Allied and its competitors.

Is Allied's EBITDA Margin % too high?

Allied's current EBITDA Margin % is -1,889.29%.

How does Allied's EBITDA Margin % compare to CBDY and PLSH?

Allied's EBITDA Margin % of -1,889.29% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Drug Manufacturers company?

The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Allied and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allied's current EBITDA Margin % is -1,889.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Allied stock overvalued right now?

Allied (ALID) has a current EBITDA Margin % of -1,889.29%. The current EBITDA Margin % is -1,889.29%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Allied (ALID), the current EBITDA Margin % is -1,889.29% as of Nov. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allied Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies CBDY PLSH STEK AKAN PTPI NXEN KAYS GCAND SKYI OWPC ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 XSWX:GALD LSE:HLN XSWX:SDZ HKSE:03692 XTAE:TEVA SHSE:688506

Address 460 Doyle Avenue, Suite 200, Kelowna, BC, CAN, V1Y OC2

Website https://www.allied.health

Allied Corp is an international cannabis company with a mission to help people suffering from Post-Traumatic Stress Disorder (PTSD) by researching, creating, and producing targeted cannabinoid health solutions. The company uses an evidence-informed scientific approach to make this mission possible through cutting-edge pharmaceutical research and development, plant-based production, and the development of therapeutic products. The company operates in two segments, which include Allied and Allied Colombia. Its geographical segments consist of Colombia and Canada. The company's revenue is comprised of sales of cannabis products.